BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26159519)

  • 21. Overall genomic pattern is a predictor of outcome in neuroblastoma.
    Janoueix-Lerosey I; Schleiermacher G; Michels E; Mosseri V; Ribeiro A; Lequin D; Vermeulen J; Couturier J; Peuchmaur M; Valent A; Plantaz D; Rubie H; Valteau-Couanet D; Thomas C; Combaret V; Rousseau R; Eggert A; Michon J; Speleman F; Delattre O
    J Clin Oncol; 2009 Mar; 27(7):1026-33. PubMed ID: 19171713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.
    Suo C; Deng W; Vu TN; Li M; Shi L; Pawitan Y
    Biol Direct; 2018 Jul; 13(1):14. PubMed ID: 30012197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
    Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
    Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Identification of the breakpoint-flanking markers on chromosomes 1 and 17 of a constitutional translocation T(1;17)(P36;Q12-21) in a patient with neuroblastoma].
    Laureys GG
    Verh K Acad Geneeskd Belg; 1995; 57(5):389-422. PubMed ID: 8571670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
    Peterson JF; Aggarwal N; Smith CA; Gollin SM; Surti U; Rajkovic A; Swerdlow SH; Yatsenko SA
    Oncotarget; 2015 Aug; 6(22):18845-62. PubMed ID: 26299921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?
    Vandesompele J; Speleman F; Van Roy N; Laureys G; Brinskchmidt C; Christiansen H; Lampert F; Lastowska M; Bown N; Pearson A; Nicholson JC; Ross F; Combaret V; Delattre O; Feuerstein BG; Plantaz D
    Med Pediatr Oncol; 2001 Jan; 36(1):5-10. PubMed ID: 11464905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
    N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma.
    Chicard M; Boyault S; Colmet Daage L; Richer W; Gentien D; Pierron G; Lapouble E; Bellini A; Clement N; Iacono I; Bréjon S; Carrere M; Reyes C; Hocking T; Bernard V; Peuchmaur M; Corradini N; Faure-Conter C; Coze C; Plantaz D; Defachelles AS; Thebaud E; Gambart M; Millot F; Valteau-Couanet D; Michon J; Puisieux A; Delattre O; Combaret V; Schleiermacher G
    Clin Cancer Res; 2016 Nov; 22(22):5564-5573. PubMed ID: 27440268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
    Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Why Is Aneuploidy Associated with Favorable Outcome in Neuroblastoma?
    Tonini GP
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
    Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
    Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation.
    Ando K; Ohira M; Ozaki T; Nakagawa A; Akazawa K; Suenaga Y; Nakamura Y; Koda T; Kamijo T; Murakami Y; Nakagawara A
    Int J Cancer; 2008 Nov; 123(9):2087-94. PubMed ID: 18726896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction.
    Morowitz M; Shusterman S; Mosse Y; Hii G; Winter CL; Khazi D; Wang Q; King R; Maris JM
    Mod Pathol; 2003 Dec; 16(12):1248-56. PubMed ID: 14681326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ARID1B alterations identify aggressive tumors in neuroblastoma.
    Lee SH; Kim JS; Zheng S; Huse JT; Bae JS; Lee JW; Yoo KH; Koo HH; Kyung S; Park WY; Sung KW
    Oncotarget; 2017 Jul; 8(28):45943-45950. PubMed ID: 28521285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease.
    Ramraj SK; Aravindan S; Somasundaram DB; Herman TS; Natarajan M; Aravindan N
    Oncotarget; 2016 Apr; 7(14):18605-19. PubMed ID: 26921195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of whole chromosome X predicts prognosis of neuroblastoma patients with numerical genomic profile.
    Parodi S; Pistorio A; Erminio G; Ognibene M; Morini M; Garaventa A; Gigliotti AR; Haupt R; Frassoni F; Pezzolo A
    Pediatr Blood Cancer; 2019 May; 66(5):e27635. PubMed ID: 30688024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
    Fransson S; Martinez-Monleon A; Johansson M; Sjöberg RM; Björklund C; Ljungman G; Ek T; Kogner P; Martinsson T
    Sci Rep; 2020 Dec; 10(1):22432. PubMed ID: 33384420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroblastoma patient-derived xenograft cells cultured in stem-cell promoting medium retain tumorigenic and metastatic capacities but differentiate in serum.
    Persson CU; von Stedingk K; Bexell D; Merselius M; Braekeveldt N; Gisselsson D; Arsenian-Henriksson M; Påhlman S; Wigerup C
    Sci Rep; 2017 Aug; 7(1):10274. PubMed ID: 28860499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic and epigenetic alterations in neuroblastoma.
    Tonini GP; Romani M
    Cancer Lett; 2003 Jul; 197(1-2):69-73. PubMed ID: 12880962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Clin Cancer Res; 2003 Oct; 9(13):4835-40. PubMed ID: 14581355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.